Global Oncology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Summary

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.

When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.

Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.

Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.

According to APO Research, The global Oncology Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Oncology Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Oncology Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Oncology Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Oncology Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Oncology Drugs include Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer and Amgen, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes


This report presents an overview of global market for Oncology Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Oncology Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Oncology Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oncology Drugs revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Oncology Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Oncology Drugs revenue, projected growth trends, production technology, application and end-user industry.


Oncology Drugs Segment by Company

Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences

Oncology Drugs Segment by Type

Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others

Oncology Drugs Segment by Application

Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory or Lung Cancer
Others

Oncology Drugs Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Oncology Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncology Drugs industry.
Chapter 3: Detailed analysis of Oncology Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncology Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Market Analysis by Type
1.2.1 Global Oncology Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy (Biologic Therapy)
1.2.5 Hormonal Therapy
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Global Oncology Drugs Market Size Growth Rate by Application: 2020 VS 2024 VS 2031
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Respiratory or Lung Cancer
1.3.7 Others
1.4 Global Market Growth Prospects
1.5 Global Oncology Drugs Growth Trends by Region
1.5.1 Global Oncology Drugs Market Size by Region: 2020 VS 2024 VS 2031
1.5.2 Oncology Drugs Market Size by Region (2020-2025)
1.5.3 Oncology Drugs Market Size by Region (2026-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
1.8 Years Considered
2 Global Oncology Drugs Market Dynamics
2.1 Oncology Drugs Industry Trends
2.2 Oncology Drugs Industry Drivers
2.3 Oncology Drugs Industry Opportunities and Challenges
2.4 Oncology Drugs Industry Restraints
3 Competitive Landscape by Company
3.1 Global Oncology Drugs Revenue by Company (2020-2025)
3.2 Global Oncology Drugs Players Revenue Ranking, 2023 VS 2024 VS 2025
3.3 Global Oncology Drugs Key Company Head office and Area Served
3.4 Global Oncology Drugs Company, Product Type & Application
3.5 Global Oncology Drugs Company Establishment Date
3.6 Market Competitive Analysis
3.6.1 Global Oncology Drugs Market CR5 and HHI
3.6.2 Global Top 5 and 10 Oncology Drugs Players Market Share by Revenue in 2024
3.6.3 2024 Oncology Drugs Tier 1, Tier 2, and Tier 3
4 Oncology Drugs Market by Type
4.1 Global Oncology Drugs Market Size by Type (2020 VS 2024 VS 2031)
4.2 Global Oncology Drugs Market Size by Type (2020-2031)
4.3 Global Oncology Drugs Market Size Share by Type (2020-2031)
5 Oncology Drugs Market by Application
5.1 Global Oncology Drugs Market Size by Application (2020 VS 2024 VS 2031)
5.2 Global Oncology Drugs Market Size by Application (2020-2031)
5.3 Global Oncology Drugs Market Size Share by Application (2020-2031)
6 Company Profiles
6.1 Roche
6.1.1 Roche Comapny Information
6.1.2 Roche Business Overview
6.1.3 Roche Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.1.4 Roche Oncology Drugs Product Portfolio
6.1.5 Roche Recent Developments
6.2 Celgene
6.2.1 Celgene Comapny Information
6.2.2 Celgene Business Overview
6.2.3 Celgene Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.2.4 Celgene Oncology Drugs Product Portfolio
6.2.5 Celgene Recent Developments
6.3 Novartis
6.3.1 Novartis Comapny Information
6.3.2 Novartis Business Overview
6.3.3 Novartis Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.3.4 Novartis Oncology Drugs Product Portfolio
6.3.5 Novartis Recent Developments
6.4 Bristol-Myers Squibb
6.4.1 Bristol-Myers Squibb Comapny Information
6.4.2 Bristol-Myers Squibb Business Overview
6.4.3 Bristol-Myers Squibb Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.4.4 Bristol-Myers Squibb Oncology Drugs Product Portfolio
6.4.5 Bristol-Myers Squibb Recent Developments
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Comapny Information
6.5.2 Johnson & Johnson Business Overview
6.5.3 Johnson & Johnson Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.5.4 Johnson & Johnson Oncology Drugs Product Portfolio
6.5.5 Johnson & Johnson Recent Developments
6.6 Merck & Co.
6.6.1 Merck & Co. Comapny Information
6.6.2 Merck & Co. Business Overview
6.6.3 Merck & Co. Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.6.4 Merck & Co. Oncology Drugs Product Portfolio
6.6.5 Merck & Co. Recent Developments
6.7 AstraZeneca
6.7.1 AstraZeneca Comapny Information
6.7.2 AstraZeneca Business Overview
6.7.3 AstraZeneca Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.7.4 AstraZeneca Oncology Drugs Product Portfolio
6.7.5 AstraZeneca Recent Developments
6.8 Pfizer
6.8.1 Pfizer Comapny Information
6.8.2 Pfizer Business Overview
6.8.3 Pfizer Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.8.4 Pfizer Oncology Drugs Product Portfolio
6.8.5 Pfizer Recent Developments
6.9 Amgen
6.9.1 Amgen Comapny Information
6.9.2 Amgen Business Overview
6.9.3 Amgen Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.9.4 Amgen Oncology Drugs Product Portfolio
6.9.5 Amgen Recent Developments
6.10 Eli Lilly
6.10.1 Eli Lilly Comapny Information
6.10.2 Eli Lilly Business Overview
6.10.3 Eli Lilly Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.10.4 Eli Lilly Oncology Drugs Product Portfolio
6.10.5 Eli Lilly Recent Developments
6.11 AbbVie
6.11.1 AbbVie Comapny Information
6.11.2 AbbVie Business Overview
6.11.3 AbbVie Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.11.4 AbbVie Oncology Drugs Product Portfolio
6.11.5 AbbVie Recent Developments
6.12 Takeda
6.12.1 Takeda Comapny Information
6.12.2 Takeda Business Overview
6.12.3 Takeda Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.12.4 Takeda Oncology Drugs Product Portfolio
6.12.5 Takeda Recent Developments
6.13 Astellas
6.13.1 Astellas Comapny Information
6.13.2 Astellas Business Overview
6.13.3 Astellas Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.13.4 Astellas Oncology Drugs Product Portfolio
6.13.5 Astellas Recent Developments
6.14 Ipsen
6.14.1 Ipsen Comapny Information
6.14.2 Ipsen Business Overview
6.14.3 Ipsen Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.14.4 Ipsen Oncology Drugs Product Portfolio
6.14.5 Ipsen Recent Developments
6.15 Sanofi
6.15.1 Sanofi Comapny Information
6.15.2 Sanofi Business Overview
6.15.3 Sanofi Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.15.4 Sanofi Oncology Drugs Product Portfolio
6.15.5 Sanofi Recent Developments
6.16 Bayer
6.16.1 Bayer Comapny Information
6.16.2 Bayer Business Overview
6.16.3 Bayer Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.16.4 Bayer Oncology Drugs Product Portfolio
6.16.5 Bayer Recent Developments
6.17 Biogen Idec
6.17.1 Biogen Idec Comapny Information
6.17.2 Biogen Idec Business Overview
6.17.3 Biogen Idec Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.17.4 Biogen Idec Oncology Drugs Product Portfolio
6.17.5 Biogen Idec Recent Developments
6.18 Teva
6.18.1 Teva Comapny Information
6.18.2 Teva Business Overview
6.18.3 Teva Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.18.4 Teva Oncology Drugs Product Portfolio
6.18.5 Teva Recent Developments
6.19 Otsuka
6.19.1 Otsuka Comapny Information
6.19.2 Otsuka Business Overview
6.19.3 Otsuka Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.19.4 Otsuka Oncology Drugs Product Portfolio
6.19.5 Otsuka Recent Developments
6.20 Eisai
6.20.1 Eisai Comapny Information
6.20.2 Eisai Business Overview
6.20.3 Eisai Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.20.4 Eisai Oncology Drugs Product Portfolio
6.20.5 Eisai Recent Developments
6.21 Merck KGaA
6.21.1 Merck KGaA Comapny Information
6.21.2 Merck KGaA Business Overview
6.21.3 Merck KGaA Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.21.4 Merck KGaA Oncology Drugs Product Portfolio
6.21.5 Merck KGaA Recent Developments
6.22 Gilead Sciences
6.22.1 Gilead Sciences Comapny Information
6.22.2 Gilead Sciences Business Overview
6.22.3 Gilead Sciences Oncology Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.22.4 Gilead Sciences Oncology Drugs Product Portfolio
6.22.5 Gilead Sciences Recent Developments
7 North America
7.1 North America Oncology Drugs Market Size (2020-2031)
7.2 North America Oncology Drugs Market Size by Type
7.2.1 North America Oncology Drugs Market Size by Type (2020-2025)
7.2.2 North America Oncology Drugs Market Size by Type (2026-2031)
7.2.3 North America Oncology Drugs Market Share by Type (2020-2031)
7.3 North America Oncology Drugs Market Size by Application
7.3.1 North America Oncology Drugs Market Size by Application (2020-2025)
7.3.2 North America Oncology Drugs Market Size by Application (2026-2031)
7.3.3 North America Oncology Drugs Market Share by Application (2020-2031)
7.4 North America Oncology Drugs Market Size by Country
7.4.1 North America Oncology Drugs Market Size by Country (2020 VS 2024 VS 2031)
7.4.2 North America Oncology Drugs Market Size by Country (2020-2025)
7.4.3 North America Oncology Drugs Market Size by Country (2026-2031)
7.4.4 North America Oncology Drugs Market Share by Country (2020-2031)
7.4.5 United States
7.4.6 Canada
7.4.7 Mexico
8 Europe
8.1 Europe Oncology Drugs Market Size (2020-2031)
8.2 Europe Oncology Drugs Market Size by Type
8.2.1 Europe Oncology Drugs Market Size by Type (2020-2025)
8.2.2 Europe Oncology Drugs Market Size by Type (2026-2031)
8.2.3 Europe Oncology Drugs Market Share by Type (2020-2031)
8.3 Europe Oncology Drugs Market Size by Application
8.3.1 Europe Oncology Drugs Market Size by Application (2020-2025)
8.3.2 Europe Oncology Drugs Market Size by Application (2026-2031)
8.3.3 Europe Oncology Drugs Market Share by Application (2020-2031)
8.4 Europe Oncology Drugs Market Size by Country
8.4.1 Europe Oncology Drugs Market Size by Country (2020 VS 2024 VS 2031)
8.4.2 Europe Oncology Drugs Market Size by Country (2020-2025)
8.4.3 Europe Oncology Drugs Market Size by Country (2026-2031)
8.4.4 Europe Oncology Drugs Market Share by Country (2020-2031)
8.4.5 Germany
8.4.6 France
8.4.7 U.K.
8.4.8 Italy
8.4.9 Russia
8.4.10 Nordic Countries
9 China
9.1 China Oncology Drugs Market Size (2020-2031)
9.2 China Oncology Drugs Market Size by Type
9.2.1 China Oncology Drugs Market Size by Type (2020-2025)
9.2.2 China Oncology Drugs Market Size by Type (2026-2031)
9.2.3 China Oncology Drugs Market Share by Type (2020-2031)
9.3 China Oncology Drugs Market Size by Application
9.3.1 China Oncology Drugs Market Size by Application (2020-2025)
9.3.2 China Oncology Drugs Market Size by Application (2026-2031)
9.3.3 China Oncology Drugs Market Share by Application (2020-2031)
10 Asia (Excluding China)
10.1 Asia Oncology Drugs Market Size (2020-2031)
10.2 Asia Oncology Drugs Market Size by Type
10.2.1 Asia Oncology Drugs Market Size by Type (2020-2025)
10.2.2 Asia Oncology Drugs Market Size by Type (2026-2031)
10.2.3 Asia Oncology Drugs Market Share by Type (2020-2031)
10.3 Asia Oncology Drugs Market Size by Application
10.3.1 Asia Oncology Drugs Market Size by Application (2020-2025)
10.3.2 Asia Oncology Drugs Market Size by Application (2026-2031)
10.3.3 Asia Oncology Drugs Market Share by Application (2020-2031)
10.4 Asia Oncology Drugs Market Size by Country
10.4.1 Asia Oncology Drugs Market Size by Country (2020 VS 2024 VS 2031)
10.4.2 Asia Oncology Drugs Market Size by Country (2020-2025)
10.4.3 Asia Oncology Drugs Market Size by Country (2026-2031)
10.4.4 Asia Oncology Drugs Market Share by Country (2020-2031)
10.4.5 Japan
10.4.6 South Korea
10.4.7 Taiwan
10.4.8 Southeast Asia
10.4.9 India
10.4.10 Australia
11 South America, Middle East & Africa
11.1 South America, Middle East & Africa Oncology Drugs Market Size (2020-2031)
11.2 South America, Middle East & Africa Oncology Drugs Market Size by Type
11.2.1 South America, Middle East & Africa Oncology Drugs Market Size by Type (2020-2025)
11.2.2 South America, Middle East & Africa Oncology Drugs Market Size by Type (2026-2031)
11.2.3 South America, Middle East & Africa Oncology Drugs Market Share by Type (2020-2031)
11.3 South America, Middle East & Africa Oncology Drugs Market Size by Application
11.3.1 South America, Middle East & Africa Oncology Drugs Market Size by Application (2020-2025)
11.3.2 South America, Middle East & Africa Oncology Drugs Market Size by Application (2026-2031)
11.3.3 South America, Middle East & Africa Oncology Drugs Market Share by Application (2020-2031)
11.4 South America, Middle East & Africa Oncology Drugs Market Size by Country
11.4.1 South America, Middle East & Africa Oncology Drugs Market Size by Country (2020 VS 2024 VS 2031)
11.4.2 South America, Middle East & Africa Oncology Drugs Market Size by Country (2020-2025)
11.4.3 South America, Middle East & Africa Oncology Drugs Market Size by Country (2026-2031)
11.4.4 South America, Middle East & Africa Oncology Drugs Market Share by Country (2020-2031)
11.4.5 Brazil
11.4.6 South Africa
11.4.7 Saudi Arabia
11.4.8 Turkey
11.4.9 Argentina
11.4.9 UAE
11.4.9 Egypt
11.4.9 Chile
12 Concluding Insights
13 Appendix
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources
13.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings